Concentration and high avidity of pneumococcal antibodies persist at least 4 years after immunization with pneumococcal conjugate vaccine in infancy

Clinical and Vaccine Immunology

Volumn 20, Issue 7, 2013, Pages 1034-1040

  Ekström, Nina ^a   Åhman, Heidi ^a,b   Palmu, Arto ^a   Grönholm, Sinikka ^a   Kilpi, Terhi ^a   Käyhty, Helena ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE;

ACTIVE IMMUNIZATION; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; FOLLOW UP; HUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; STREPTOCOCCUS PNEUMONIA;

ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; CHILD, PRESCHOOL; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; INFANT; MALE; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

EID: 84880490207     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00039-13     Document Type: Article

References (34)

1. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K. 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 19:187-195. (Pubitemid 30167436)
2. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, Oluwalana C, Vaughan A, Obaro SK, Leach A, McAdam KP, Biney E, Saaka M, Onwuchekwa U, Yallop F, Pierce NF, Greenwood BM, Adegbola RA. 2005. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365:1139-1146. (Pubitemid 40417563)
3. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. 2003. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 349:1341-1348. (Pubitemid 37186212)
4. O'Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, Brown L, Kumar G, Parkinson A, Hu D, Hackell J, Chang I, Kohberger R, Siber G, Santosham M. 2003. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 362:355-361. (Pubitemid 36945058)
5. Black S, Shinefield H. 2002. Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from northern California. Eur. J. Pediatr. 161(Suppl. 2):S127-S131. (Pubitemid 35435550)
6. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, Takala A, Käyhty H, Karma P, Kohberger R, Siber G, Mäkelä PH. 2001. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344:403-409. (Pubitemid 32128672)
7. Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. 2003. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr. Infect. Dis. J. 22:10-16. (Pubitemid 36091771)
8. Prymula R, Schuerman L. 2009. 10-Valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev. Vaccines 8:1479-1500.
9. Bryant KA, Block SL, Baker SA, Gruber WC, Scott DA. 2010. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics 125:866-875.
10. Black S, Eskola J, Whitney C, Shinefield H. 2008. Pneumococcal conjugate vaccine and pneumococcal common protein vaccines. In Plotkin SA, Orenstein WA, Offit PA (ed), Vaccines, 5th ed. Saunders Elsevier, Philadelphia, PA.
11. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T. 2009. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374:893-902.
12. Usinger WR, Lucas AH. 1999. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect. Immun. 67:2366-2370. (Pubitemid 29200494)
13. Schlesinger Y, Granoff DM. 1992. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA 267:1489-1494.
14. Goldblatt D, Vaz AR, Miller E. 1998. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J. Infect. Dis. 177:1112-1115. (Pubitemid 28155915)
15. Joseph H, Miller E, Dawson M, Andrews N, Feavers I, Borrow R. 2001. Meningococcal serogroup A avidity indices as a surrogate marker of priming for the induction of immunologic memory after vaccination with a meningococcal A/C conjugate vaccine in infants in the United Kingdom. J. Infect. Dis. 184:661-662. (Pubitemid 32783564)
16. Lee YC, Kelly DF, Yu LM, Slack MP, Booy R, Heath PT, Siegrist CA, Moxon RE, Pollard AJ. 2008. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of highquality antibody. Clin. Infect. Dis. 46:186-192. (Pubitemid 351269156)
17. Auckland C, Gray S, Borrow R, Andrews N, Goldblatt D, Ramsay M, Miller E. 2006. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J. Infect. Dis. 194: 1745-1752. (Pubitemid 44902007)
18. Palmu A, Kaijalainen T, Verho J, Herva E, Mäkelä PH, Kilpi T. 2002. Long-term efficacy of the sevenvalent PncCRM vaccine on nasopharyngeal carriage, abstr 24. Abstr. 3rd Int. Symp. Pneumococci Pneumococcal Dis.
19. Palmu AA, Verho J, Jokinen J, Karma P, Kilpi TM. 2004. The sevenvalent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children. Pediatr. Infect. Dis. J. 23:732-738. (Pubitemid 39063288)
20. Kilpi T, Åhman H, Jokinen J, Lankinen KS, Palmu A, Savolainen H, Grönholm M, Leinonen M, Hovi T, Eskola J, Käyhty H, Bohidar N, Sadoff JC, Mäkelä PH. 2003. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin. Infect. Dis. 37:1155-1164. (Pubitemid 37372502)
21. Concepcion NF, Frasch CE. 2001. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcalpolysaccharide enzyme-linked immunosorbent assay. Clin. Diagn. Lab. Immunol. 8:266-272. (Pubitemid 32217054)
22. World Health Organization. 2009. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines. Proposed replacement of Technical Report Series no. 927, annex 2, ECBS. World Health Organization, Geneva, Switzerland.
23. Nurkka A, Lahdenkari M, Palmu A, Käyhty H. 2004. Salivary antibodies induced by the seven-valent PncCRM conjugate vaccine in the Finnish Otitis Media Vaccine Trial. Vaccine 23:298-304. (Pubitemid 39463045)
24. Käyhty H, Åhman H, Rönnberg PR, Tillikainen R, Eskola J. 1995. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J. Infect. Dis. 172:1273-1278.
25. Ekström N, Åhman H, Verho J, Jokinen J, Väkeväinen M, Kilpi T, Käyhty H. 2005. Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. Infect. Immun. 73:369-377. (Pubitemid 40041129)
26. Simell B, Lahdenkari M, Reunanen A, Käyhty H, Väkeväinen M. 2008. Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins. Clin. Vaccine Immunol. 15:1391-1397.
27. Goldblatt D, Southern J, Ashton L, Richmond P, Burbidge P, Tasevska J, Crowley-Luke A, Andrews N, Morris R, Borrow R, Cartwright K, Miller E. 2006. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr. Infect. Dis. J. 25:312-319.
28. Huebner RE, Mbelle N, Forrest B, Madore DV, Klugman KP. 2004. Long-term antibody levels and booster responses in South African children immunized with nonavalent pneumococcal conjugate vaccine. Vaccine 22:2696-2700. (Pubitemid 38900643)
29. Madhi SA, Adrian P, Kuwanda L, Jassat W, Jones S, Little T, Soininen A, Cutland C, Klugman KP. 2007. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 25:2451-2457. (Pubitemid 46389429)
30. Schuerman L, Prymula R, Chrobok V, Dieussaert I, Poolman J. 2007. Kinetics of the immune response following pneumococcal PD conjugate vaccination. Vaccine 25:1953-1961. (Pubitemid 46227682)
31. Silfverdal SA, Skerlikova H, Zanova M, Papuchova D, Traskine M, Borys D, Schuerman L. 2011. Anamnestic immune response in 3- to 4-year-old children previously immunized with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as 2-dose or 3-dose priming and a booster dose in the first year of life. Pediatr. Infect. Dis. J. 30:e155- e163.
32. Madhi SA, Klugman KP, Kuwanda L, Cutland C, Käyhty H, Adrian P. 2009. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J. Infect. Dis. 199:1168-1176.
33. Nurkka A, Åhman H, Yaich M, Eskola J, Käyhty H. 2001. Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines, PncD and PncT. Vaccine 20:194-201. (Pubitemid 32905332)
34. Åhman H, Käyhty Lehtonen H, Leroy H, Froeschle O, Jand Eskola J. 1998. Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. Pediatr. Infect. Dis. J. 17:211-216.